The entry mechanism used by a model retrovirus.
The entry mechanism used by a model retrovirus.
批准号:
7008544
负责人:
Gregory B Melikian
金额:
$35.76万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-15 至 2007-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Enveloped viruses enter cells either by fusing their envelope directly to a host cell membrane or by fusing to endosomal membrane after being internalized. Fusion in the first entry pathway is triggered by binding to cognate receptor(s), whereas fusion in endocytotic pathway is initiated by low pH within the endosome. Strong evidence exists that the Env glycoprotein of the retrovirus, avian sarcoma and leukosis virus (ASLV), uses both receptor binding and low pH to enter the cell: it undergoes initial conformational changes at the plasma membrane as a result of receptor binding, and, after endocytosis, undergoes final changes induced by low pH within endosomes. The unprecedented utilization of this dual triggering mechanism allows the sequential refolding of the ASLV Env that leads to fusion to be better delineated than possible for other viruses. The low pH-requirement for fusion between cells expressing ASLV Env and cognate receptor-expressing cells has been unambiguously demonstrated, but the requirement for low pH during virus entry is still controversial. The pH-dependence of virus-cell and virus-liposome fusion will be rigorously investigated, using lipid and content mixing assays. The identity of the pH-sensitive steps of ASLV Env-induced fusion will be determined by arresting sequential stages of fusion and testing whether low pH is required to proceed to the subsequent stage. For many unrelated viral proteins, a common structural motif referred to as a six-helix bundle, has emerged; there is compelling evidence that this structure is critical for fusion. The sequence homology between ASLV Env and other fusion proteins with known structures strongly indicates its propensity to form a six-helix bundle. Whether ASLV Env does fold into a bundle to promote fusion will be tested by determining if Env-derived synthetic peptides abolish cell-cell fusion, as was the case for other viral proteins that fold into bundles. Delineating the mechanism of ASLV Env-induced fusion will provide insight into the basic principles by which important human pathogens, such as HIV, Ebola, and flu viruses enter cells and could therefore suggest new antiviral strategies against viral pathogens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biophysics Core
-
批准号:10508448
-
项目类别:
-
资助金额:$77.98万
-
财政年份:2022
-
负责人:Gregory B Melikian
-
依托单位:
Biophysics Core
-
批准号:10650878
-
项目类别:
-
资助金额:$80.21万
-
财政年份:2022
-
负责人:Gregory B Melikian
-
依托单位:
Molecular Interactions of HIV-1 with the Nuclear Pore Complex
-
批准号:10241258
-
项目类别:
-
资助金额:$136.92万
-
财政年份:2019
-
负责人:Gregory B Melikian
-
依托单位:
Molecular Interactions of HIV-1 with the Nuclear Pore Complex
-
批准号:10462620
-
项目类别:
-
资助金额:$134.88万
-
财政年份:2019
-
负责人:Gregory B Melikian
-
依托单位:
Inhibition of viral entry by interferon-induced proteins
-
批准号:10418696
-
项目类别:
-
资助金额:$35.6万
-
财政年份:2018
-
负责人:Gregory B Melikian
-
依托单位:
Inhibition of viral entry by interferon-induced proteins
-
批准号:10190798
-
项目类别:
-
资助金额:$35.6万
-
财政年份:2018
-
负责人:Gregory B Melikian
-
依托单位:
Imaging of Single HIV-1 Uncoating and Transport to the nucleus
-
批准号:9354023
-
项目类别:
-
资助金额:$59.65万
-
财政年份:2017
-
负责人:Gregory B Melikian
-
依托单位:
Kinetic Determinants of HIV Neutralization
-
批准号:7929311
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2010
-
负责人:Gregory B Melikian
-
依托单位:
Kinetic Determinants of HIV Neutralization
-
批准号:8142878
-
项目类别:
-
资助金额:$19.18万
-
财政年份:2010
-
负责人:Gregory B Melikian
-
依托单位:
Functional Characterization of the Hepatitis C Virus E1-E2 Glycoproteins
-
批准号:7522862
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2009
-
负责人:Gregory B Melikian
-
依托单位:
Functional Characterization of the Hepatitis C Virus E1-E2 Glycoproteins
-
批准号:8116923
-
项目类别:
-
资助金额:$15.55万
-
财政年份:2009
-
负责人:Gregory B Melikian
-
依托单位:
Functional Characterization of the Hepatitis C Virus E1-E2 Glycoproteins
-
批准号:7897844
-
项目类别:
-
资助金额:$3.7万
-
财政年份:2009
-
负责人:Gregory B Melikian
-
依托单位:
Entry Mechanisms used by a model retrovirus
-
批准号:7370296
-
项目类别:
-
资助金额:$36.25万
-
财政年份:2003
-
负责人:Gregory B Melikian
-
依托单位:
The Mechanism of Arenavirus Entry into Cells
-
批准号:10623143
-
项目类别:
-
资助金额:$41.76万
-
财政年份:2003
-
负责人:Gregory B Melikian
-
依托单位:
Entry mechanisms used by a model retrovirus
-
批准号:8577613
-
项目类别:
-
资助金额:$36.66万
-
财政年份:2003
-
负责人:Gregory B Melikian
-
依托单位:
Entry mechanisms used by a model retrovirus
-
批准号:8656664
-
项目类别:
-
资助金额:$36.66万
-
财政年份:2003
-
负责人:Gregory B Melikian
-
依托单位:
The Mechanism of Arenavirus Entry into Cells
-
批准号:9889875
-
项目类别:
-
资助金额:$41.76万
-
财政年份:2003
-
负责人:Gregory B Melikian
-
依托单位:
Entry Mechanisms used by a model retrovirus
-
批准号:8116813
-
项目类别:
-
资助金额:$38.29万
-
财政年份:2003
-
负责人:Gregory B Melikian
-
依托单位:
The Mechanism of Arenavirus Entry into Cells
-
批准号:9755767
-
项目类别:
-
资助金额:$44.56万
-
财政年份:2003
-
负责人:Gregory B Melikian
-
依托单位:
The entry mechanism used by a model retrovirus.
-
批准号:7176092
-
项目类别:
-
资助金额:$35.71万
-
财政年份:2003
-
负责人:Gregory B Melikian
-
依托单位:
国内基金
海外基金
登录
查看更多内容
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
-
批准号:82371634
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵福军
-
依托单位:
PRNP调控巨噬细胞M2极化并减弱吞噬功能促进子宫内膜异位症进展的机制研究
-
批准号:82371651
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵栋
-
依托单位:
CBP/p300-HADH轴在基础胰岛素分泌调节中的作用和机制研究
-
批准号:82370798
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:王晓
-
依托单位:
生物钟核受体Rev-erbα在缺血性卒中神经元能量代谢中的改善作用及机制研究
-
批准号:82371332
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:胡琴
-
依托单位:
TIPE2调控巨噬细胞M2极化改善睑板腺功能障碍的作用机制研究
-
批准号:82371028
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵慧
-
依托单位:
慢性炎症诱发骨丢失的机制及外泌体靶向治疗策略研究
-
批准号:82370889
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:傅德皓
-
依托单位:
配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
-
批准号:82371616
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨成
-
依托单位:
超声驱动压电效应激活门控离子通道促眼眶膜内成骨的作用及机制研究
-
批准号:82371103
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:阮静
-
依托单位:
5'-tRF-GlyGCC通过SRSF1调控RNA可变剪切促三阴性乳腺癌作用机制及干预策略
-
批准号:82372743
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:陈卓佳
-
依托单位:
骨髓ISG+NAMPT+中性粒细胞介导抗磷脂综合征B细胞异常活化的机制研究
-
批准号:82371799
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:杨程德
-
依托单位: